{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-047994","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2024-11-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.657176+00:00","generated_at":"2026-05-29T13:27:40.544743+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"GT Biopharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M minimum","bullets":["Nasdaq letter on Nov 21, 2024: stockholders' equity fell below $2.5M required for continued listing.","Company does not meet market value of listed securities or net income alternatives.","Must submit compliance plan by Jan 6, 2025; Nasdaq may grant up to 180-day extension.","If plan not accepted, Company may appeal to Nasdaq Hearings Panel.","Stock continues trading under GTBP; no assurance of regaining compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-047994","json":"https://secwatch.observer/filing/0001493152-24-047994.json","markdown":"https://secwatch.observer/filing/0001493152-24-047994.md","text":"https://secwatch.observer/filing/0001493152-24-047994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315224047994/0001493152-24-047994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315224047994/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T13:27:40.544743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}